<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059952</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001430</org_study_id>
    <nct_id>NCT04059952</nct_id>
  </id_info>
  <brief_title>Mechanism of Action of Electroconvulsive Therapy</brief_title>
  <acronym>MoA-ECT</acronym>
  <official_title>Mechanism of Action of Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational neuroimaging study assessing the effects of ECT on the brains of
      patients with unipolar and bipolar depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aims to use functional connectivity magnetic resonance imaging (fcMRI) to study
      patients with unipolar and bipolar depression receiving ECT. Patients will be scanned before
      and after a full course of ECT and clinical measures for depression severity and memory will
      be obtained at the same times.The project has the following aims and hypothesis: (1) to
      determine the therapeutic antidepressant mechanism of action of ECT at the circuit level (2)
      to determine the mechanism of action of iatrogenic amnesia caused by ECT at the circuit level
      (3) to study the use of fcMRI as a state biomarker for depression (4) to study the use of
      fcMRI as a predictor of response for depression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Functional Connectivity of Key Nodes</measure>
    <time_frame>Through Treatment Completion, Average of 2 Months</time_frame>
    <description>Measured by Magnetic Resonance Imaging, Key Nodes include Subgenual Cingulate, Dorsal Anterior Cingulate, Nucleus Accumbens, Hippocampus, Amygdala and Dorsolateral Prefrontal Cortex</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Functional Connectivity of Memory Circuits</measure>
    <time_frame>Through Treatment Completion, Average of 2 Months</time_frame>
    <description>Measured by Magnetic Resonance Imaging, Memory Circuits Include Hippocampus and Dorsolateral Prefrontal Memory Hubs</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Unipolar Depression</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Unipolar Depression</arm_group_label>
    <description>Patients diagnosed with Major Depressive Disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar Depression</arm_group_label>
    <description>Patients diagnosed with Bipolar I or II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Patients without psychiatric diagnoses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroconvulsive Therapy</intervention_name>
    <description>Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.</description>
    <arm_group_label>Bipolar Depression</arm_group_label>
    <arm_group_label>Unipolar Depression</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male and Female Patients with Unipolar or Bipolar Depression Between the Ages of 18 and 65
        Being Treated with ECT as Part of Outpatient Psychiatric Care, or Healthy Controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females Between Ages of 18 and 65

          -  Diagnosis of Major Depressive Disorder without Psychotic Features or Bipolar I/II

          -  Requiring ECT Treatment as Part of Psychiatric Care

        Exclusion Criteria:

          -  Comorbid diagnoses of Major Depressive Disorder with Psychotic Features,
             Schizoaffective Disorder, Schizophrenia or Dementia

          -  History of Psychosis

          -  Substance Use Disorder (Abuse or Dependence) with Active Use Within Last 6 Months

          -  Severe or Unstable Medical Illness

          -  Medical Contraindication to Anesthesia or ECT (e.g., Recent Myocardial Infarction)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Camprodon, MD MPH PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Funes, MS</last_name>
    <phone>6177248780</phone>
    <email>cjfunes@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Funes, MS</last_name>
      <phone>617-724-8780</phone>
      <email>cjfunes@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joan A Camprodon, MD MPH PhD</investigator_full_name>
    <investigator_title>Chief of Division of Neuropsychiatry, Director of TMS Clinic, Director of Lab for Neuropsychiatry and Neuromodulation</investigator_title>
  </responsible_party>
  <keyword>Electroconvulsive Therapy</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All identifying information (e.g., name, medical record number, date of birth) will be removed from data that will be shared with other researchers or research databases. It will not be possible to link the information back to the participant.</ipd_description>
    <ipd_time_frame>Data will become available at study completion for an undefined amount of time.</ipd_time_frame>
    <ipd_access_criteria>Data will be accessible by researchers who have access to research databases at the NIH.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

